Campylobacter glycans and glycopeptides
AssigneeNational Research Council of Canada
InventorsNoel M. Young, Jean-Robert Brisson, John Francis Kelly, David C. Watson, Harold C. Jarrell, Christine M. Szymanski
Life of this patent
Estimating the term…
Loading patent…
AssigneeNational Research Council of Canada
InventorsNoel M. Young, Jean-Robert Brisson, John Francis Kelly, David C. Watson, Harold C. Jarrell, Christine M. Szymanski
Estimating the term…
Multiple strains and species of Campylobacter share a common glycan moiety which is present in a plurality of surface-exposed glycoproteins. This glycan has the formula: GalNAc-a1, 4-GalNAc-a1,4-[Glc-β1,3]GalNAc-a1,4-GalNAc-a1,4-GalNAc-a1,3-Bac, wherein Bac is 2, 4-diacetamido-2,4,6-trideoxy-D-glucopyranose. This glycan and immunologically active fragments of it have use as vaccines against campylobacter infection in humans and animals. As well, antibodies which specifically bind these compounds may be provided. Such antibodies and vaccines may be used to prevent or neutralize campylobacter infections in livestock thereby preventing this pathogen from entering the human food chain. The glycan may be linked to one or more amino acids to form a glycopeptide. As well, a method for determining the glycan structure of an intact glycoprotein consists of subjecting a sample to high resolution magic angle spinning nuclear magnetic resonance (HR-MAS-NMR) spectroscopy.
An isolated and purified heptasaccharide of formula GalNAc-a1,4-GalNAc-a1,4-[Glc-β1,3]GalNAc-a1,4-GalNAc-a1,4-GalNAc-a1,3-Bac, wherein Bac is 2,4-diacetamido-2,4,6-trideoxy-D-gluco-pyranose.
An isolated and purified compound that is a heptasaccharide of formula GalNAc-a1,4-GalNAc-a1,4-[Glc-β1,3]GalNAc-a1,4-GalNAc-a1,4-GalNAc-a1,3-Bac, wherein Bac is 2,4-diacetamido-2,4,6-trideoxy-D-gluco-pyranose linked to one amino acid or an oligopeptide.
Dependencies are inferred from the claim text.